Obesity: Pathophysiology, Health Risks, Evidence-Based Treatment Options, and Prevention Strategies in Adults

Obesity is a chronic, relapsing disease characterized by excessive adipose tissue that impairs health. Clinically, it is commonly defined using body mass index (BMI) thresholds: BMI ≥30 kg/m² denotes obesity, with further subclassification into class I (30–34.9), class II (35–39.9), and class III (≥40). While BMI is useful for population screening, clinicians also consider central adiposity (e.g., waist circumference), metabolic risk markers, and functional impairment because body composition varies by age, sex, and ethnicity. Obesity is not simply a matter of willpower; it arises from complex interactions among genetics, behavior, neuroendocrine regulation, environment, and socioeconomic factors.

At the core of obesity biology is dysregulation of energy homeostasis. The hypothalamus integrates hormonal and neural signals that govern appetite and satiety. Leptin, produced by adipocytes, normally communicates energy sufficiency to the brain; in obesity, leptin levels rise yet appetite suppression becomes blunted due to leptin resistance. Insulin also contributes to satiety and peripheral nutrient signaling, and insulin resistance commonly coexists with obesity. Other gut-derived hormones such as ghrelin (promotes hunger) and GLP-1 (enhances satiety and slows gastric emptying) further modulate intake. In addition, reward pathways in the mesolimbic system can amplify cravings in response to palatable foods, stress, and cues, tilting behavior toward excessive caloric consumption.

Obesity also reshapes metabolism and inflammation. Excess adipose tissue increases free fatty acid flux and promotes ectopic fat deposition in liver, muscle, and pancreas. This promotes insulin resistance and the progression from prediabetes to type 2 diabetes. Adipose inflammation involves macrophage infiltration and pro-inflammatory cytokines such as TNF-α and IL-6, which worsen metabolic dysfunction. Dyslipidemia (elevated triglycerides, reduced HDL cholesterol) and hypertension often accompany obesity, increasing cardiovascular risk. Obesity is associated with obstructive sleep apnea, nonalcoholic fatty liver disease (hepatic steatosis and steatohepatitis), gallbladder disease, osteoarthritis, and certain cancers. Respiratory mechanics are also affected: higher abdominal mass reduces lung volumes and contributes to dyspnea.

Psychological and behavioral dimensions matter, but they are best understood as contributors within a biological context. Depression, stress, trauma, and disordered eating patterns can increase intake through emotional eating, impaired self-regulation, or changes in stress hormones like cortisol. However, weight stigma can worsen mental health and can indirectly contribute to poorer outcomes by discouraging care, intensifying stress, and undermining sustainable behavior change.

Evidence-based management is multidisciplinary and typically includes lifestyle therapy, pharmacotherapy, and for eligible patients, bariatric or metabolic surgery. Intensive lifestyle interventions aim for calorie reduction and improved diet quality (higher protein and fiber, reduced ultra-processed foods), along with structured physical activity and behavioral strategies such as self-monitoring, goal setting, and relapse planning. Pharmacologic therapy targets pathways involved in appetite regulation and nutrient handling. For example, GLP-1 receptor agonists and related agents increase satiety, reduce gastric emptying, and improve glycemic control; additional options include combinations such as phentermine/topiramate or naltrexone/bupropion, each with distinct mechanisms and safety profiles.

For patients with severe obesity (BMI ≥40) or BMI ≥35 with obesity-related comorbidities, bariatric surgery can produce substantial and durable weight loss, improve insulin sensitivity, and reduce cardiometabolic risk. Procedures such as sleeve gastrectomy and Roux-en-Y gastric bypass alter gastrointestinal anatomy and hormonal signaling (including increased incretin effect), contributing to long-term metabolic improvements. Perioperative care requires management of nutritional deficiencies, adherence to vitamin/mineral supplementation, and monitoring for complications.

Prevention focuses on maintaining energy balance across the life course: promoting healthy food environments, reducing sedentary behavior, supporting physical activity, and addressing sleep and stress. Public health approaches include early interventions in childhood and reducing structural barriers to healthy choices. Clinically, risk assessment should include family history, metabolic laboratory screening when indicated, and evaluation for comorbid conditions such as sleep apnea.

Importantly, clinical communication should be person-centered and non-stigmatizing. Framing obesity as a medical condition fosters engagement in evidence-based care and supports adherence. A comprehensive plan evaluates causes, targets specific comorbidities, and uses measurable outcomes such as percent weight loss, blood pressure, A1c, lipid profiles, and functional status.

Source: [TBones2993] (Original post referencing obesity as a health-related issue)